Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has reiterated its Buy rating for Rocket Pharmaceuticals, maintaining a price target of $38.
September 30, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity has reiterated its Buy rating for Rocket Pharmaceuticals, maintaining a price target of $38.
The reaffirmation of a Buy rating and a specific price target by Canaccord Genuity is a positive signal for investors, suggesting confidence in Rocket Pharmaceuticals' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100